{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:02:59Z","timestamp":1778554979669,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.biopha.2011.02.013","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T04:25:59Z","timestamp":1306211159000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells"],"prefix":"10.1016","volume":"65","author":[{"given":"Zhenglan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maosheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2011.02.013_bib0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.biopha.2011.02.013_bib0010","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.biopha.2011.02.013_bib0015","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2011.02.013_bib0020","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6022","key":"10.1016\/j.biopha.2011.02.013_bib0025","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph[prime] translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2011.02.013_bib0030","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat Struct Biol"},{"issue":"8","key":"10.1016\/j.biopha.2011.02.013_bib0035","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","article-title":"The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr\/abl","volume":"99","author":"He","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2011.02.013_bib0040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/MCB.21.3.840-853.2001","article-title":"The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl","volume":"21","author":"Zhang","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.biopha.2011.02.013_bib0045","first-page":"7587","article-title":"A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins","volume":"13","author":"McWhirter","year":"1993","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.biopha.2011.02.013_bib0050","first-page":"1269","article-title":"The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells","volume":"12","author":"Tauchi","year":"1998","journal-title":"Int J Oncol"},{"issue":"8","key":"10.1016\/j.biopha.2011.02.013_bib0055","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2003-03-0811","article-title":"Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571","volume":"102","author":"Beissert","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2011.02.013_bib0060","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"Green","year":"1988","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2011.02.013_bib0065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"issue":"52","key":"10.1016\/j.biopha.2011.02.013_bib0070","doi-asserted-by":"crossref","first-page":"20805","DOI":"10.1073\/pnas.0706574105","article-title":"Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes","volume":"104","author":"Herce","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.biopha.2011.02.013_bib0075","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","article-title":"A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus","volume":"272","author":"Vive\u2018s","year":"1997","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.biopha.2011.02.013_bib0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-5793(98)00426-8","article-title":"Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts","volume":"427","author":"Kato","year":"1998","journal-title":"FEBS Lett"},{"issue":"14","key":"10.1016\/j.biopha.2011.02.013_bib0085","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1128\/MCB.21.14.4773-4784.2001","article-title":"Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo","volume":"21","author":"Ezhevsky","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.biopha.2011.02.013_bib0090","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/mthe.2001.0279","article-title":"Intracellular delivery of a Tat-eGFP fusion protein into muscle cells","volume":"3","author":"Caron","year":"2001","journal-title":"Mol Ther"},{"issue":"5433","key":"10.1016\/j.biopha.2011.02.013_bib0095","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.285.5433.1569","article-title":"In vivo protein transduction: delivery of a biologically active protein into the mouse","volume":"285","author":"Schwarze","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.biopha.2011.02.013_bib0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/17425240902887029","article-title":"TAT-based drug delivery system \u2013 new directions in protein delivery for new hopes?","volume":"6","author":"Rapoport","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"10.1016\/j.biopha.2011.02.013_bib0105","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/4042","article-title":"Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration","volume":"4","author":"Nagahara","year":"1998","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.biopha.2011.02.013_bib0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1098-2795(199706)47:2<140::AID-MRD3>3.0.CO;2-M","article-title":"Expression of bonnet monkey (Macaca radiata) zona pellucida-3 (ZP3) in a prokaryotic system and its immunogenicity","volume":"47","author":"Kaul","year":"1997","journal-title":"Mol Reprod Dev"},{"issue":"3","key":"10.1016\/j.biopha.2011.02.013_bib0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/protein\/gzi014","article-title":"A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells","volume":"18","author":"Albarran","year":"2005","journal-title":"Protein Eng Des Sel"},{"issue":"1","key":"10.1016\/j.biopha.2011.02.013_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-006-9044-4","article-title":"The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis","volume":"35","author":"Jiang","year":"2008","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10.1016\/j.biopha.2011.02.013_bib0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/108729002760070795","article-title":"Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates","volume":"12","author":"Koppelhus","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.biopha.2011.02.013_bib0130","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2011.02.013_bib0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ccr.2009.08.012","article-title":"Imatinib resistance and progression of CML to blast crisis: somatic hypermutation aiding the way","volume":"16","author":"Strout","year":"2009","journal-title":"Cancer Cell"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333221100031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333221100031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:47:46Z","timestamp":1760093266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333221100031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S075333221100031X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2011.02.013","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2011.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2011 Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}